Scinai Immunotherapeutics Ltd. American Depositary Shares
Compare this stock
SCNI Stock Report Card
$
54%
Performance
Score:
10/100
SCNI returned -49.31% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Earnings
Score:
100/100
SCNI has missed earnings 1 times in the last 20 quarters.
Volatility
Score:
20/100
SCNI has had a lower than average amount of volatility over the last 12 months giving it a score of 20 of 100.
Scinai Immunotherapeutics Ltd. American Depositary Shares Summary
Nasdaq / SCNI
Healthcare
Biotechnology
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
SCNI scored highly on our reportcard. Here are some similar companies and how they performed.
